KRAS and hematopoietic and lymphoid system neoplasm: High expression of KRAS is associated with poor prognosis in blood cancer (GSE2658, HR = 0.55, Cox p-value = 0.00147, Figure 6A), breast cancer (GSE11121, HR = 1.45, Cox p-value = 0.000745.